A new development in the H1N1 Vaccine Saga is unfolding in Canada.
Whereas health officials are pushing for an acceleration of the vaccination program, there is evidence of so-called “unusual adverse reactions” including three recently recorded deaths directly resulting from the vaccine.
In the meantime, health authorities have called for the withdrawal of 170,000 (higher risk) doses of the vaccine produced by GlaxoSmithKline. The initiative, of which the importance is being downplayed, is said to have come from the manufacturer GlaxoSmithKline, which expressed concern on higher than normal adverse reactions to the vaccine.
“Canada’s H1N1 flu vaccine manufacturer has asked the provinces to temporarily discontinue vaccinating Canadians from a lot of vaccine shipped in October due to a higher risk of adverse reactions, says a Manitoba health official.
